1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

The Medicines Company launched its novel anticoagulant, Angiomax (bivalirudin), in the US in January 2001 following approval by the US FDA in December of the previous year. Bivalirudin was subsequently approved for use in the EU in 2004 under the trade name Angiox. Bivalirudin, a small molecule peptide, is a direct thrombin inhibitor. It is administered intravenously during the acute phase of ACS and is indicated for use in patients undergoing PCI.

Scope

- Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Aricept for the top seven countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for ACS
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Aricept performance
- Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table Of Contents

Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 18
3.1.3 Prognosis 19
3.1.4 Quality of Life 20
3.2 Symptoms 20
4 Disease Management 22
4.1 Treatment Overview 22
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29
6 Angiomax (bivalirudin) 34
6.1 Overview 34
6.2 Efficacy 35
6.3 Safety 35
6.4 SWOT Analysis 36
6.5 Forecast 36
7 Appendix 38
7.1 Bibliography 38
7.2 Abbreviations 44
7.3 Methodology 48
7.4 Forecasting Methodology 48
7.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 48
7.4.2 Diagnosed Acute Coronary Syndrome Patients 49
7.4.3 Percent Drug-Treated Patients 50
7.4.4 General Pricing Assumptions 50
7.4.5 Individual Drug Assumptions 52
7.4.6 Generic Erosion 52
7.5 Physicians and Specialists Included in this Study 53
7.6 About the Authors 56
7.6.1 Author 56
7.6.2 Reviewer 56
7.6.3 Global Head of Healthcare 57
7.7 About GlobalData 58
7.8 Disclaimer 58

1.1 List of Tables

Table 1: Antiplatelet Agents that Inhibit Platelet Activation 16
Table 2: Anticoagulants that Inhibit the Coagulatory Cascade 16
Table 3: Symptoms of Acute Coronary Syndrome 21
Table 4: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI) 25
Table 5: Most Prescribed Drugs for ACS by Class in the Global Markets, 2014 27
Table 6: Leading Treatments for Acute Coronary Syndrome, 2014 33
Table 7: Product Profile - Angiomax 34
Table 8: Angiomax (bivalirudin) SWOT Analysis, 2014 36
Table 9: Global Sales Forecasts ($m) for Angiomax, 2013-2023 37
Table 10: Price Sources and Calculations, by Country 51
Table 11: Physicians Surveyed, By Country 55

1.2 List of Figures

Figure 1: The ACS Timeline and the Scope of GlobalData's ACS Report and Forecast 14
Figure 2: Progression of Coronary Artery Disease, Atherosclerotic Plaque Rupture, Thrombosis, and Acute Coronary Syndrome 15
Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis 17
Figure 4: Electrocardiography in the Diagnosis of ACS 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

  • $ 59500
  • Industry report
  • January 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

2017 World Transfusion Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

2017 World Transfusion Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

  • $ 43500
  • Industry report
  • January 2017
  • by Venture Planning Group

This comprehensive 68-country report from VPGMarketResearch.com provides granular data and analysis not available from any other source. The report is designed to help current suppliers and potential market ...

2017 World Blood Typing, Grouping and Infectious Disease Screening Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

2017 World Blood Typing, Grouping and Infectious Disease Screening Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

  • $ 43500
  • Industry report
  • January 2017
  • by Venture Planning Group

This comprehensive 68-country report from VPGMarketResearch.com provides granular data and analysis not available from any other source. The report is designed to help current suppliers and potential market ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.